Responses

Download PDFPDF

UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Ranibizumab for neovascular AMD in eyes with good baseline visual acuity.
    • Muhammad S Raja, Consultant Ophthalmologist
    • Other Contributors:
      • Manuel Saldana, Craig Goldsmith and Benjamin JL Burton

    We read with interest and congratulate Lee et al1 on publishing the largest study to date on visual outcomes reported upto 36 months, with intravitreal ranibizumab treatment for neovascular age related macular degeneration (AMD). However we do not agree with their conclusion that this is the first publication to focus on the visual outcomes on this subgroup of patients, excluded from treatment by the NICE UK criteria. O...

    Show More
    Conflict of Interest:
    None declared.